Artiva Biotherapeutics, Inc. ARTV Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Artiva Biotherapeutics, Inc. (ARTV) reported unrealized gains (losses) on available-for-sale securities of -$121K in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Artiva Biotherapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 193.8% year-over-year, from $129K to -$121K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric tracks the unrealized gains or losses on investment securities classified as available-for-sale, which are recorded directly to equity rather than the income statement. It reflects the market-to-market performance of the company's treasury or investment portfolio. This provides transparency into the latent value or impairment of assets held for liquidity purposes.